YU50402A - Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze - Google Patents
Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinazeInfo
- Publication number
- YU50402A YU50402A YU50402A YUP50402A YU50402A YU 50402 A YU50402 A YU 50402A YU 50402 A YU50402 A YU 50402A YU P50402 A YUP50402 A YU P50402A YU 50402 A YU50402 A YU 50402A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- substituted lower
- compounds
- substituted
- nr9r10
- cyano
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- QRRCMVPZJCHBLQ-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-2,7-diamine Chemical compound C1=NC(N)=NC2=NC(N)=CC=C21 QRRCMVPZJCHBLQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17826100P | 2000-01-25 | 2000-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU50402A true YU50402A (sh) | 2005-11-28 |
Family
ID=22651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU50402A YU50402A (sh) | 2000-01-25 | 2001-01-23 | Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1254137A1 (es) |
| JP (1) | JP4047010B2 (es) |
| KR (1) | KR20020065939A (es) |
| CN (1) | CN1395578A (es) |
| AP (1) | AP2002002586A0 (es) |
| AR (1) | AR030044A1 (es) |
| AU (1) | AU2542501A (es) |
| BG (1) | BG106850A (es) |
| BR (1) | BR0107751A (es) |
| CA (1) | CA2397961C (es) |
| CO (1) | CO5261549A1 (es) |
| CR (1) | CR6706A (es) |
| CZ (1) | CZ20022475A3 (es) |
| DZ (1) | DZ3266A1 (es) |
| EA (1) | EA200200643A1 (es) |
| EE (1) | EE200200405A (es) |
| GT (1) | GT200100016A (es) |
| HN (1) | HN2001000013A (es) |
| HU (1) | HUP0204141A3 (es) |
| IL (1) | IL150545A0 (es) |
| IS (1) | IS6443A (es) |
| MA (1) | MA26868A1 (es) |
| MX (1) | MXPA02007221A (es) |
| NO (1) | NO20023527L (es) |
| OA (1) | OA12161A (es) |
| PA (1) | PA8510701A1 (es) |
| PE (1) | PE20011066A1 (es) |
| PL (1) | PL356802A1 (es) |
| SK (1) | SK10632002A3 (es) |
| SV (1) | SV2002000294A (es) |
| TN (1) | TNSN01014A1 (es) |
| WO (1) | WO2001055147A1 (es) |
| YU (1) | YU50402A (es) |
| ZA (1) | ZA200205879B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| AU2002246855B2 (en) | 2000-10-23 | 2005-12-22 | Smithkline Beecham Corporation | Novel compounds |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE370952T1 (de) | 2002-04-19 | 2007-09-15 | Smithkline Beecham Corp | Neue verbindungen |
| BR0316680A (pt) * | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| TW200502236A (en) * | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| CN101014600A (zh) * | 2004-09-21 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类 |
| WO2006104917A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
| JP2008535822A (ja) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| AR053346A1 (es) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38 |
| TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| BRPI0613604A2 (pt) * | 2005-07-21 | 2011-01-18 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos |
| ES2351939T3 (es) * | 2005-08-09 | 2011-02-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas. |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| FR2910813B1 (fr) * | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| MX2011005720A (es) * | 2008-12-01 | 2011-06-17 | Merck Patent Gmbh | Pirido [4,3-d] pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina contra cancer. |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| WO2014151682A1 (en) * | 2013-03-14 | 2014-09-25 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR101671404B1 (ko) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20012444B (en) * | 1994-11-14 | 2001-05-25 | Warner Lambert Company Us | 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| DE69939168D1 (de) * | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
-
2001
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 EP EP01900591A patent/EP1254137A1/en not_active Withdrawn
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Application Discontinuation
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/en not_active Application Discontinuation
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 CA CA002397961A patent/CA2397961C/en not_active Expired - Fee Related
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
-
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU50402A (sh) | Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze | |
| BG106594A (en) | Pteridinones as kinase inhibitors | |
| AP2000001964A0 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| RU2005127052A (ru) | Соединения тиенопиримидина и их применение | |
| CL2008001230A1 (es) | Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. | |
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| NZ627709A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
| BG107161A (en) | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors | |
| GEP20063915B (en) | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS | |
| IL150883A0 (en) | Pyrimidine compounds | |
| BRPI0517461A (pt) | compostos farmacêuticos | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| UY27198A1 (es) | Nuevos compuestos antiinflamatorios de bencimidazol | |
| HUP0300798A2 (hu) | Szubsztituált triazolopirimidin-származékok és alkalmazásuk rákellenes hatóanyagként és ezeket tartalmazó gyógyszerkészítmények | |
| UA83091C2 (en) | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors | |
| EP1233950A4 (en) | 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS | |
| CA2997039A1 (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| MXPA04002042A (es) | Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer. | |
| MXPA03004023A (es) | Compuestos quimicos. | |
| DK0888356T3 (da) | Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere | |
| CN117751104A (zh) | 一类具有激酶抑制功能的化合物及其制备和应用 | |
| TH53887A (th) | ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส |